Relationships between FSH, inhibin B, anti-Mullerian hormone, and testosterone during long-term treatment with the GnRH-agonist histrelin in patients with prostate cancer

European Journal of Endocrinology

Volumn 162, Issue 1, 2010, Pages 177-181

  Eldar Geva, Talia ^a   Liberty, Gad ^a   Chertin, Boris ^a   Fridmans, Alon ^a   Farkas, Amicur ^a   Margalioth, Ehud J ^a   Spitz, Irving M ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; FOLLITROPIN; HISTRELIN; INHIBIN B; MUELLERIAN INHIBITING FACTOR; TESTOSTERONE; DRUG DERIVATIVE; GONADORELIN; INHIBIN;

AGED; ARTICLE; CANCER PATIENT; CANCER THERAPY; CLINICAL ARTICLE; FOLLITROPIN BLOOD LEVEL; HUMAN; IMPLANT; LONG TERM CARE; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SERTOLI CELL; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; BLOOD; COMPARATIVE STUDY; DRUG POTENTIATION; PROSTATE TUMOR; TIME;

AGED; AGED, 80 AND OVER; ANTI-MULLERIAN HORMONE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INHIBINS; LONG-TERM CARE; MALE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TESTOSTERONE; TIME FACTORS;

EID: 73949096453     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0366     Document Type: Article

References (29)

1. Catalona WJ. Management of cancer of the prostate. New England Journal of Medicine 1994 331 996-1004.
2. Santen RJ, Demers LM, Max DT, Smith J, Stein BS & Glode LM. Long term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma. Journal of Clinical Endocrinology and Metabolism 1984 58 397-400.
3. Chertin B, Spitz IM, Lindenberg T, Algur N, Zer T, Kuzma P, Young AJ, Catane R & Farkas A. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. Journal of Urology 2000 163 838-844.
4. Schlegel PN & Histrelin Study Group. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer. Journal of Urology 2006 175 1353-1358.
5. Fridmans A, Chertin B, Koulikov D, Lindenberg T, Gelber H, Leiter C, Farkas A & Spitz IM. Reversibility of androgen deprivation therapy in patients with prostate cancer. Journal of Urology 2005 173 784-789.
6. de Kretser DM, Buzzard JJ, Okuma Y, O'Connor AE, Hayashi T, Lin SY, Morrison JR, Loveland KL & Hedger MP. The role of activin, follistatin and inhibin in testicular physiology. Molecular and Cellular Endocrinology 2004 225 57-64.
7. Jensen TK, Andersson AM, Hjollund NH, Scheike T, Kolstad H, Giwercman A, Henriksen TB, Ernst E, Bonde JP, Olsen J, McNeilly A, Groome NP & Skakkebaek NE. Inhibin B as a serum marker of spermatogenesis: correlation to differences in sperm concentration and follicle-stimulating hormone levels. A study of 349 Danish men. Journal of Clinical Endocrinology and Metabolism 1997 82 4059-4063.
8. Josso N, Picard JY, Rey R & di Clemente N. Testicular anti-Mullerian hormone: history, genetics, regulation and clinical applications. Pediatric Endocrinology Reviews 2006 3 347-358.
9. Racine C, Rey R, Forest MG, Louis F, Ferre A, Huhtaniemi I, Josso N & di Clemente N. Receptors for anti-Mullerian hormone on Leydig cells are responsible for its effects on steroidogenesis and cell differentiation. PNAS 1998 95 594-599.
10. Fujisawa M, Yamasaki T, Okada H & Kamidono S. The significance of anti-Mullerian hormone concentration in seminal plasma for spermatogenesis. Human Reproduction 2002 17 968-970.
11. Hellman L, Bradlow HL, Freed S, Levin J, Rosenfeld RS, Whitmore WF & Zumoff B. The effect of flutamide on testosterone metabolism and the plasma levels of androgens and gonadotropins. Journal of Clinical Endocrinology and Metabolism 1997 45 1224-1229.
12. Foresta C, Bettella A, Spolaore D, Merico M, Rossato M & Ferlin A. Suppression of the high endogenous levels of plasma FSH in infertile men are associated with improved Sertoli cell function as reflected by elevated levels of plasma inhibin B. Human Reproduction 2004 19 1431-1437.
13. Hadziselimovic F, Senn E & Bandhauer K. Effect of treatment with chronic gonadotropin releasing hormone agonist on human testis. Journal of Urology 1987 38 1048-1050.
14. Huhtaniemi I, Nikula H, Parvinen M & Rannikko S. Histological and functional changes of the testis tissue during GnRH agonist treatment of prostatic cancer. American Journal of Clinical Oncology 1988 11 S11-S15.
15. Murthy V, Norman AR, Barbachano Y, Parker CC & Dearnaley DP. Long-term effects of a short course of neoadjuvant luteinizing hormone-releasing hormone analogue and radical radiotherapy on the hormonal profile in patients with localized prostate cancer. BJU International 2007 99 1380-1382.
16. Giagulli VA & Carbone D. Hormonal control of inhibin B in men. Journal of Endocrinological Investigation 2006 29 706-713.
17. Raivio T, Wikström AM & Dunkel L. Treatment of gonadotropin-deficient boys with recombinant human FSH: long-term observation and outcome. European Journal of Endocrinology 2007 156 105-111.
18. Young J, Couzinet B, Chanson P, Brailly S, Loumaye E & Schaison G. Effects of human recombinant luteinizing hormone and follicle-stimulating hormone in patients with acquired hypogonadotropic hypogonadism: Study of Sertoli and Leydig cell secretions and interactions. Journal of Clinical Endocrinology and Metabolism 2000 85 3239-3244.
19. Lahlou N & Roger M. Inhibin B in pubertal development and pubertal disorders. Seminars in Reproductive Medicine 2004 22 165-175.
20. Yao B & Kawaminami M. Stimulation of annexin a5 expression by gonadotropin releasing hormone (GnRH) in the Leydig cells of rats. Journal of Reproduction and Development 2008 54 259-264.
21. Andersson AM, Müller J & Skakkebaek NE. Different roles of prepubertal and postpubertal germ cells and Sertoli cells in the regulation of serum inhibin B levels. Journal of Clinical Endocrinology and Metabolism 1998 83 4451-4458.
22. Fujisawa M, Yamazaki T, Fujioka H & Takenaka A. Differential regulation of inhibin subunits by germ cells in human testes. Archives of Andrology 2004 50 339-345.
23. Rey R, Lukas-Croisier C, Lasala C & Bedecarrás P. AMH/MIS: what we know already about the gene, the protein and its regulation. Molecular and Cellular Endocrinology 2003 211 21-31.
24. Teixeira J, Maheswaran S & Donahoe PK. Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocrine Reviews 2001 22 657-674.
25. Appasamy M, Muttukrishna S, Pizzey AR, Ozturk O, Groome NP, Serhal P & Jauniaux E. Relationship between male reproductive hormones, sperm DNA damage and markers of oxidative stress in infertility. Reproductive Biomedicine Online 2007 14 159-165.
26. Rey R. Assessment of seminiferous tubule function (anti-Mülerian hormone). Baillière's Best Practice & Research. Clinical Endocrinology & Metabolism 2000 14 399-408.
27. Lasala C, Carré-Eusèbe D, Picard JY & Rey R. Subcellular and molecular mechanisms regulating anti-Müllerian hormone gene expression in mammalian and nonmammalian species. DNA and Cell Biology 2004 23 572-585.
28. Young J, Chanson P, Salenave S, Noel M, Brailly S, O'Flaherty M, Schaison G & Rey R. Testicular anti-Mullerian hormone secretion is stimulated by recombinant human FSH in patients with congenital hypogonadotropic hypogonadism. Journal of Clinical Endocrinology and Metabolism 2005 90 724-728.
29. Young J, Rey R, Couzinet B, Chanson P, Josso N & Schaison G. Anti-Mullerian hormone in patients with hypogonadotropic hypogonadism. Journal of Clinical Endocrinology and Metabolism 1999 84 2696-2699.